“With more than 33 years of medical device experience and a proven track record of success leading both private and public companies, Greg will be instrumental in guiding the future strategic direction of Cardiac Dimensions,” said Jan Garfinkle, member of Cardiac Dimensions’ Board of Directors. “Based on his extensive knowledge of the interventional cardiology space, we believe he is the ideal choice to take Cardiac Dimensions to the next level.”
Throughout his career, Mr. Casciaro has served in numerous executive leadership roles, most recently as the President and CEO of AccessClosure, Inc., an interventional cardiology medical device company that was acquired by Cardinal Health, Inc. in 2014. Prior to that, he served as President and CEO of XTENT, Inc., a medical device company, recognized for developing a revolutionary drug-eluting stent platform. Prior to XTENT, Mr. Casciaro was President and CEO of Orquest Inc., which was acquired by DePuy Acromed, a division of Johnson & Johnson. Prior to that, he was President and CEO of General Surgical Innovations, which was acquired by U.S. Surgical, a division of Tyco.
He has held several senior level positions with Devices for Vascular Intervention, a division of Guidant Corporation, and North American Instrument Corporation. In addition to his operating roles, Greg is on the Board of Directors for Apama Medical, Trireme Medical Inc., and Cardica. Greg graduated from Marquette University in Milwaukee, WI with a B.A. in Business Administration.
Under the leadership of Mr. Casciaro, Cardiac Dimensions will continue to build on the success of its CE-Marked, minimally invasive product, Carillon® Mitral Contour System®, which was specifically designed to treat functional (secondary) mitral regurgitation, or FMR, in heart failure patients. Millions of people worldwide suffer from the condition, which has been associated with high rates of mortality, reduced functional capacity, poor quality of life and an increase in patient hospitalizations. Current mainstream therapies to address FMR are limited.
“Cardiac Dimensions has an innovative platform that is designed to address the unmet needs of heart failure patients and the related condition of FMR,” Mr. Casciaro said. “The clinical data available for this therapy have demonstrated that it benefits patients significantly and, we believe, holds incredible promise for the future. I am excited to lead this talented team forward as we increase access to the therapy through continued global commercialization and expanded clinical work.”
About Cardiac Dimensions
Cardiac Dimensions is a privately held medical device company that has developed the only right-sided, minimally invasive product specifically designed to treat functional (secondary) mitral regurgitation or FMR. The company’s novel interventional technology, The Carillon® Mitral Contour System®, is a percutaneous mitral annuloplasty treatment option that can be deployed rapidly and safely, utilizing standard interventional techniques. The implantable device consists of a distal anchor and a proximal anchor connected by a shaping ribbon and utilizes the heart’s venous anatomy to reshape the mitral annulus. This approach allows for reduction of the dilated annulus, addressing a root cause of functional mitral regurgitation (FMR). Carillon has demonstrated compelling efficacy, significantly improving patients’ symptoms, mitral regurgitation and quality of life. In addition, all adjunctive treatment options remain available after using Carillon, making it an ideal first-line therapy for FMR.
Cardiac Dimensions has operations in Kirkland, Washington; Sydney, Australia and Offenbach, Germany. For more information, visit the company’s web site: http://www.cardiacdimensions.com.
Cardiac Dimensions, Carillon and Mitral Contour System are registered trademarks of Cardiac Dimensions.
Vice President Sales and Marketing